SKI-II was shown to be a novel and alternative activator of Nrf2, independently of sphingosine kinase inhibition, with potential benefits for diseases where Keap1 activity is increased such as COPD. This evidence concerns the gene KEAP1 and chronic obstructive pulmonary disease.